Healthcare and life sciences companies face a unique challenge: every translated document carries clinical, regulatory, or patient safety implications. Kobalt has been translating healthcare content for over 14 years, with zero regulatory rejections due to translation errors.
See the data ↓These are structural problems in how healthcare organizations handle multilingual regulatory and clinical content. They repeat across every organization expanding into new markets.
A term translated differently between your Spanish and Portuguese patient information leaflets creates regulatory risk. Enterprise LSPs rotate linguists across accounts, so your regulatory terminology resets with every team change.
5-15% industry avg revision rateJoint Commission International and national health authorities expect documented evidence of translation quality processes. Most providers deliver a final file with no audit trail of who translated, who reviewed, or what quality checks were applied.
Machine translation on Safety Data Sheets can paraphrase legally mandated hazard statements. Under EU CLP Regulation 1272/2008, paraphrased H-codes and P-codes produce non-compliant documents. The risk is not theoretical.
Section 8 of every SDS requires country-specific occupational exposure limits. Germany uses MAK values. France uses VME/VLE. Spain uses LEP. A translation that copies one country's limits into another's SDS is non-compliant.
REACH Article 31(9) requires SDS updates without delay when new risk information emerges. Each update must propagate to ALL language versions. Organizations managing 50+ SDS across 24 EU languages lose track of which versions are current.
24 EU official languages requiredGeneral translation agencies may deliver acceptable quality for marketing content, but lack the specialized knowledge required for clinical trial documentation, pharmaceutical regulatory submissions, or SDS compliance across multiple jurisdictions.
Kobalt's healthcare practice combines dedicated specialist linguists, regulatory domain knowledge, and quality processes designed to meet the requirements of healthcare accreditation and pharmaceutical compliance.
Our longest healthcare partnership spans over 14 years with one of Europe's largest private healthcare groups. The same linguists who translated their Joint Commission International accreditation documentation in 2012 still translate it today. This continuity is not a soft benefit. It is how you maintain 99%+ terminology consistency across regulatory submissions.
Quality management and translation services certifications provide the documented framework required for regulated environments. Our QA process includes independent revision by a second qualified linguist, automated terminology validation, and complete audit trails with reviewer attribution and timestamps.
Not all healthcare content carries the same regulatory exposure. Patient-facing materials, clinical documentation, and regulatory submissions follow a full human specialist workflow. Internal communications and general content follow streamlined paths. Content is routed automatically based on type and risk level.
For chemical and pharmaceutical SDS translation, we maintain regulatory terminology databases with officially mandated H-code and P-code translations, country-specific occupational exposure limit references, and version control systems tracking which SDS version has been translated to which languages.
We audit your existing translated materials, identify terminology gaps, and build client-specific termbases in memoQ Server. For pharmaceutical content, we cross-reference against regulatory databases. For SDS, we validate hazard statement translations against official GHS translation tables.
We run a controlled pilot using your actual documents across a subset of language pairs. You compare quality, turnaround, and coordination overhead against your current provider. No commitment beyond the pilot scope.
Named linguists assigned to your account with healthcare or pharmaceutical specialization. The same team handles all your content types: clinical, regulatory, patient-facing, and operational. Performance tracked through published metrics: revision rate, terminology consistency, on-time delivery.
For over 14 years, Kobalt has been the dedicated translation partner for one of Europe's largest private healthcare groups, translating clinical, regulatory, and patient-facing content including JCI accreditation documentation and bilateral insurance contracts. Content subject to external regulatory audit where terminological accuracy directly impacts accreditation outcomes. Zero critical terminology errors to date.
For a global dermatology and pharmaceutical company, Kobalt translates cosmetic product licensing documentation for regulatory market authorization governed by EU supervisory orders on cosmetics. Zero regulatory rejections due to translation errors to date. Revision rate below 1%.
| Metric | Kobalt | Industry Average |
|---|---|---|
| Revision rate | <1% | 5-15% |
| Terminology consistency | 99%+ | 85-90% |
| On-time delivery | 98.7% | 92-95% |
| Team continuity | Same linguists for 14+ years | Rotation every 6-12 months |
| Regulatory rejections | 0 to date | Not typically tracked |
We maintain regulatory terminology databases cross-referenced against official GHS translation tables. Under EU CLP Regulation 1272/2008, hazard statements (H-codes) and precautionary statements (P-codes) have exact legally mandated translations. Our linguists validate every hazard statement against the official database rather than translating freely. Automated QA checks flag any deviation from mandated text before delivery.
Yes. REACH regulation requires that Safety Data Sheets be provided in the official language(s) of each EU member state where the substance or mixture is placed on the market. Kobalt operates across all EU official languages with qualified specialist linguists for each pair. Country-specific occupational exposure limits (Section 8) are validated per jurisdiction.
ISO 9001 (Quality Management) and ISO 17100 (Translation Services). Our quality management system provides documented processes, audit trails, and reviewer attribution required for regulated healthcare environments. Our translation production platform (memoQ) holds independent SOC-2 Type 2 certification.
Standard regulatory or clinical content: 48 to 72 hours with specialist review. Urgent single-language requests: 24 to 48 hours. For multi-language SDS or regulatory submissions, our hybrid model (specialist human review on critical sections, structured QA on lower-risk sections) can reduce turnaround by 40-60% while maintaining compliance.
Yes. We have translated JCI accreditation documentation continuously for over 14 years for one of Europe's largest private healthcare groups. This content is subject to external regulatory audit, meaning terminological accuracy directly impacts whether the organization passes accreditation. Our track record: zero critical terminology errors across 14+ years.
We maintain version control systems tracking which SDS version has been translated to which languages. When a substance receives a new classification, an ATP amendment changes requirements, or new risk management information becomes available, we flag affected SDS versions across all language variants and prioritize updates according to REACH Article 31(9) requirements.
Enterprise LSPs provide coverage without depth. Project managers rotate every 6 to 12 months, resetting knowledge of your regulatory environment. Linguists are drawn from general pools and may lack healthcare specialization. Kobalt assigns dedicated specialist teams that stay on your account for years. Our longest healthcare relationship is 14+ years with the same core linguists. In regulated content, this continuity directly impacts terminology consistency and audit readiness.
Send us a sample document. We'll return a terminology analysis, quality assessment, and compliance review for your language portfolio.
Prefer email? ricard@kobaltlanguages.com